# MOTS-c: Research Overview — Peptide Supplied > A literature summary of MOTS-c (mitochondrial-derived peptide), its AMPK/folate-cycle mechanism, exercise-mimetic preclinical data, CK2 identification, and the complete absence of human intervention trials. A 16-amino-acid peptide encoded inside mitochondrial DNA, with a precisely mapped AMPK mechanism and compelling preclinical data — and zero completed human efficacy trials. ## The short version MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA type-c. It is a 16-amino-acid peptide — just 16 amino acids long — but it is unusual in one fundamental way: its gene is not in the cell's nucleus like most protein-coding genes, but inside the mitochondria, the organelles that produce cellular energy. Discovered in 2015, it is part of a class now called mitochondrial-derived peptides. In cell and animal studies, MOTS-c activates AMPK — the master energy sensor that governs how cells handle glucose and fat — by inhibiting the folate cycle and de novo purine biosynthesis, which raises a molecule called AICAR that turns AMPK on [15]. Exercise raises endogenous MOTS-c levels in muscle and blood, and exogenous MOTS-c significantly improved treadmill running capacity and grip strength in aged mice [16]. A 2024 study identified casein kinase 2 (CK2) as a direct molecular binding target [13]. Here is the necessary check: every claim about MOTS-c improving metabolism, performance, or aging in humans comes from cell or animal studies. MOTS-c is not FDA-approved for any use. It is sold as a research chemical only. This page describes what has been studied — not what the compound does in people, because that has not been tested in controlled human trials. ## What it is MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). The mitochondrial genome is a small circular DNA molecule present in hundreds of copies per cell; finding a functional peptide-coding sequence within a ribosomal RNA gene was unexpected — it required the assumption that the mitochondrial genetic code differs from the standard nuclear code at two positions. The sequence is highly conserved across mammalian species, which is a strong evolutionary indicator of biological importance. Natural MOTS-c is expressed in muscle, liver, and circulating blood; levels change with age, exercise, and metabolic state, establishing it as an endogenous signaling molecule rather than an artifact. As a research chemical it is synthesized as the 16-mer, supplied as lyophilized powder, and used for laboratory investigation only. ## How it works MOTS-c has two well-characterized actions. The first and best-studied is **metabolic: inhibition of the folate cycle and de novo purine biosynthesis** in skeletal muscle cells. Blocking these pathways causes an accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is a direct activator of AMPK — the cell's main energy-status sensor. Activated AMPK shifts the cell toward glucose uptake and fat oxidation, which is why MOTS-c is described as an insulin-sensitizer and exercise mimetic [15]. The second is **nuclear: under metabolic stress, MOTS-c translocates from the mitochondria to the nucleus** and directly regulates gene expression in an AMPK-dependent manner, including antioxidant-response-element (ARE) genes through interaction with NRF2 — the first demonstrated retrograde signaling (mitochondria-to-nucleus communication) by a mitochondrially encoded peptide [17]. The 2024 CK2 study added a third layer: MOTS-c directly binds and activates casein kinase 2 (CK2) in a tissue-specific manner — activating CK2 in muscle (driving glucose uptake and preventing atrophy) while suppressing it in fat tissue. This was identified through cell-free binding assays and confirmed in several mouse models including aged and high-fat-diet animals [13]. ## What the research shows *CK2 as a direct molecular target.* A 2024 iScience study demonstrated MOTS-c directly binding and activating CK2, with tissue-specific modulation (activation in muscle, suppression in fat) as the basis for its effects on skeletal muscle glucose uptake and prevention of atrophy. Effects were validated in young mice, aged mice, high-fat-diet models, and immobilized-limb models, as well as in cell-free binding assays [13]. *Human clinical biomarker association.* In a prospective multicenter cohort of 94 chronic hemodialysis patients (median 26.5 months follow-up), circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, P=0.05), and adding MOTS-c to the prediction model improved ROC AUC from 0.727 to 0.743 [14]. This is observational biomarker data, not an intervention trial — it shows that MOTS-c levels track with outcomes, not that giving exogenous MOTS-c changes them. *Exercise-mimetic and aging.* Exercise induces endogenous MOTS-c in skeletal muscle and circulation. Exogenous MOTS-c supplementation significantly enhanced physical performance (treadmill running capacity, P=0.000002), grip strength, and gait in aged mice at 2, 12, and 22 months, positioning MOTS-c as a mitochondrial-encoded regulator of age-dependent physical decline [16]. *Nuclear translocation and stress response.* Metabolic stress triggers MOTS-c to translocate from the mitochondria to the nucleus, where it regulates ARE and antioxidant genes through AMPK-dependent interaction with NRF2 — the first retrograde mitochondria-to-nucleus signaling by any mitochondrially encoded peptide [17]. *Comprehensive mechanism review.* A 2023 review in Journal of Translational Medicine synthesizes the MT-RNR1 encoding, AMPK/folate-cycle mechanism, nuclear translocation, exercise inducibility, and roles across metabolic, stress, and aging pathways — the current orientation reference for MOTS-c biology [15]. ## Reported effects, cautions & safety No community-anecdote reports are compiled in this desk's source material for MOTS-c, so none are presented. The following cautions come directly from the cited scientific literature. - *No human efficacy trials.* Every claim about exogenous MOTS-c improving metabolism, performance, or aging in humans comes from cell or animal studies. The sole human data are observational biomarker associations, not intervention outcomes [14]. Exogenous MOTS-c has not been tested for efficacy in human clinical trials. - *No validated human pharmacokinetics.* There is no published, measured human half-life, bioavailability, or dose-response data. Rodent doses used in studies (0.5-15 mg/kg/day) cannot be extrapolated to humans. - *Research-chemical status.* MOTS-c is not FDA-approved for any use and is sold only for laboratory research. Product purity, identity, and sterility vary by supplier and are not subject to pharmaceutical-grade oversight. - *Anti-doping prohibition.* MOTS-c is treated as a prohibited peptide in elite sport by anti-doping authorities (WADA/USADA), covered under hormone and metabolic modulator categories. Athletes face sanctions for use. - *Population-dependent effects.* A pro-diabetogenic MOTS-c mtDNA variant (m.1382A>C) and ancestry-dependent exercise responses in human studies suggest MOTS-c effects are not uniform across individuals or genetic backgrounds [15]. - *Consumer claims outpace evidence.* MOTS-c is marketed with fat-loss, longevity, and performance claims that greatly exceed the strength of the published — entirely preclinical — evidence. ## Where it fits in metabolic research MOTS-c is the most preclinical compound on this desk, and the one whose origin story is the most scientifically unusual — a peptide discovered inside the mitochondrial genome, signaling back to the nucleus, with a mechanism that overlaps with both exercise physiology and metabolic disease [15][16][17]. It has no human trial record at all, which puts it at the opposite pole from [retatrutide](/retatrutide) (Phase 3 ongoing) and [tesamorelin](/tesamorelin) (FDA-approved for a specific indication). Its interest lies in the precision of its mechanism and the open question of whether those animal-model and biomarker signals will translate. See the [comparison page](/compare) for the full side-by-side. ![MOTS-c 16-amino-acid peptide translocating from mitochondrion to nucleus with AMPK activation pathways in cold ultramarine](/images/mots-c.webp) --- A practitioner's reading desk for metabolic peptide research — citations and mechanism, not doses and not advice.